PCSK9 and prostate carcinoma: Repeating our primary MR analyses to investigate the genetically proxied association of each lipid-lowering target on BMI (S13 Table) provided little evidence for genetically proxied inhibition of PCSK9 (Beta = 0.02, 95% CI = −0.01 to 0.05, P = 0.212, SD change in BMI per SD reduction in LDL-c) as well as NPC1L1 (Beta = −0.02, 95% CI = −0.23 to 0.18, P = 0.819) on prostate cancer risk.